277 related articles for article (PubMed ID: 1707153)
1. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.
Le Roy X; Escot C; Brouillet JP; Theillet C; Maudelonde T; Simony-Lafontaine J; Pujol H; Rochefort H
Oncogene; 1991 Mar; 6(3):431-7. PubMed ID: 1707153
[TBL] [Abstract][Full Text] [Related]
2. Proto-oncogene amplification and human breast tumor phenotype.
Adnane J; Gaudray P; Simon MP; Simony-Lafontaine J; Jeanteur P; Theillet C
Oncogene; 1989 Nov; 4(11):1389-95. PubMed ID: 2554239
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells.
Dubik D; Dembinski TC; Shiu RP
Cancer Res; 1987 Dec; 47(24 Pt 1):6517-21. PubMed ID: 3677090
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
5. An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas.
Walker RA; Senior PV; Jones JL; Critchley DR; Varley JM
J Pathol; 1989 Jun; 158(2):97-105. PubMed ID: 2569035
[TBL] [Abstract][Full Text] [Related]
6. Protooncogene, growth factor, growth factor receptor, and estrogen and progesterone receptor gene expression in the immature rat uterus after treatment with estrogen and tamoxifen.
Bhattacharyya N; Ramsammy R; Eatman E; Hollis VW; Anderson WA
J Submicrosc Cytol Pathol; 1994 Apr; 26(2):147-62. PubMed ID: 8019941
[TBL] [Abstract][Full Text] [Related]
7. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
[TBL] [Abstract][Full Text] [Related]
8. The human breast carcinoma cell line SW 613-S: an experimental system to study tumor heterogeneity in relation to c-myc amplification, growth factor production and other markers (review).
Lavialle C; Modjtahedi N; Lamonerie T; Frebourg T; Landin RM; Fossar N; Lhomond G; Cassingena R; Brison O
Anticancer Res; 1989; 9(5):1265-79. PubMed ID: 2686529
[TBL] [Abstract][Full Text] [Related]
9. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
10. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK
Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for recurrent breast cancer: univariate and multivariate analyses including histologic grade and amplification of the c-erbB-2 proto-oncogene.
Tsuda H; Tsugane S; Fukutomi T; Nanasawa T; Yamamoto H; Hirohashi S
Jpn J Clin Oncol; 1992 Aug; 22(4):244-9. PubMed ID: 1359174
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G
Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033
[TBL] [Abstract][Full Text] [Related]
13. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells?
Tang RP; Kacinski B; Validire P; Beuvon F; Sastre X; Benoit P; dela Rochefordière A; Mosseri V; Pouillart P; Scholl S
J Cell Biochem; 1990 Nov; 44(3):189-98. PubMed ID: 1980125
[TBL] [Abstract][Full Text] [Related]
14. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of TGF-alpha, EGF-R, c-erbB-2, c-H-ras, c-myc, estrogen and progesterone in benign and malignant human breast lesions: a concomitant expression.
Spaventi R; Kamenjicki E; Pecina N; Grazio S; Grazio S; Pavelic J; Kusic B; Cvrtila D; Danilovic Z; Spaventi S
In Vivo; 1994; 8(2):183-9. PubMed ID: 7919121
[TBL] [Abstract][Full Text] [Related]
16. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
17. ras, c-myc and c-erbB-2 oncoproteins in human breast cancer.
Spandidos DA; Yiagnisis M; Papadimitriou K; Field JK
Anticancer Res; 1989; 9(5):1385-93. PubMed ID: 2574023
[TBL] [Abstract][Full Text] [Related]
18. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.
Tsuda H; Hirohashi S; Shimosato Y; Hirota T; Tsugane S; Yamamoto H; Miyajima N; Toyoshima K; Yamamoto T; Yokota J
Cancer Res; 1989 Jun; 49(11):3104-8. PubMed ID: 2566377
[TBL] [Abstract][Full Text] [Related]
19. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
Wilbur DC; Barrows GH
Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
[TBL] [Abstract][Full Text] [Related]
20. Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells.
Liu E; Santos G; Lee WM; Osborne CK; Benz CC
Oncogene; 1989 Aug; 4(8):979-84. PubMed ID: 2668848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
